Shots:

• The sNDA is based on the P-III ORIENT-15 clinical trial evaluates sintilimab + CT vs PBO + CT in a ratio (1:1) in 659 patients unresectable LA- recurrent or metastatic ESCC
• In an interim analysis- the therapy demonstrated an improvement in the 1EPs of OS & PFS. The results were presented at ESMO 2021
• Sintilimab is an innovative PD-1 inhibitor- jointly developed by Eli Lilly and Innovent. Additionally- Innovent has two regulatory submissions under review in China for sintilimab as 1L or 2L treatment of ESCC & NSCLC & is currently conducting 20+ clinical studies of sintilimab for multiple cancer

Click here  | Ref: PR Newswire | Image: Innovent